Articles published by BlueWind Medical, Ltd.

Three-Year Data Reinforce Revi® System as the Most Clinically Validated Implantable Tibial Neuromodulation Therapy for Urgency Urinary Incontinence

February 27, 2026

From BlueWind Medical, Ltd.

Via Business Wire

BlueWind Medical Receives FDA 510(k) Clearance for Enhanced Revi® Wearable Supporting Long-Term Treatment of Urgency Urinary Incontinence

December 16, 2025

From BlueWind Medical, Ltd.

Via Business Wire

Revi® System Demonstrates Significant and Sustained Quality of Life Benefits Across All Domains for the Majority of Patients with Urgency Urinary Incontinence at 24 Months

April 29, 2025

From BlueWind Medical, Ltd.

Via Business Wire

BlueWind Medical Announces Peer-Reviewed Data Showing Excellent Durability of Results for Revi® System at Two Years

February 07, 2025

From BlueWind Medical, Ltd.

Via Business Wire

BlueWind Medical Announces Favorable CMS Decision for 2025 Reimbursement Rates for Revi® System’s Implantable Tibial Neuromodulation Therapy

November 04, 2024

From BlueWind Medical, Ltd.

Via Business Wire

New Research from BlueWind Medical Shows Implantable Tibial Neuromodulation (iTNM), such as the Revi® System, as Effective Alternative to Sacral Neuromodulation (SNM) for Overactive Bladder and Urge Urinary Incontinence

October 31, 2024

From BlueWind Medical, Ltd.

Via Business Wire

Two-Year Revi® Therapy Data Reinforce Sustained Efficacy and Safety of Implantable Tibial NeuroModulation in Managing Urgency Urinary Incontinence

October 24, 2024

From BlueWind Medical, Ltd.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.